Literature DB >> 23292814

Personalized treatment of pain.

Jacob N Ablin1, Dan Buskila.   

Abstract

Despite advances made in its understanding and treatment, chronic pain remains an unsolved and all too common problem. One of the main obstacles to successful management of pain is the high variability of many patients regarding both response to treatment and susceptibility to adverse effects, which curtails the utility of therapeutic intervention. Understanding the causes of this variability is an important challenge which may lead to a new era in rational pain management. As described in this review, however, there currently seems to be more than one possible explanation of this variability. Rational personalized pain management must take into consideration both ever-increasing knowledge of pharmacogenetics and pharmacokinetics and a broad, clinically based attitude incorporating co-morbidities, both physical and psychiatric, and concomitant medications. Novel models for testing in-vivo pain processing, for example assessment of conditioned pain modulation (CPM), are also promising approaches to use of rational data for empirical treatment of pain. Last, listening to the patient and understanding the context in which pain has affected his or her life is an important part of maintaining the personal nature of therapeutic interaction with patients suffering from pain.

Entities:  

Mesh:

Year:  2013        PMID: 23292814     DOI: 10.1007/s11926-012-0298-7

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  43 in total

Review 1.  The potential benefits of applying a narrative analytic approach for understanding the experience of fibromyalgia: a review.

Authors:  Lindsay McMahon; Craig Murray; Jane Simpson
Journal:  Disabil Rehabil       Date:  2011-11-11       Impact factor: 3.033

2.  Widespread pain in fibromyalgia is related to a deficit of endogenous pain inhibition.

Authors:  Nancy Julien; Philippe Goffaux; Pierre Arsenault; Serge Marchand
Journal:  Pain       Date:  2005-03       Impact factor: 6.961

Review 3.  Peripheral and central mechanisms of orofacial inflammatory pain.

Authors:  Barry J Sessle
Journal:  Int Rev Neurobiol       Date:  2011       Impact factor: 3.230

4.  No pain relief from morphine? Individual variation in sensitivity to morphine and the need to switch to an alternative opioid in cancer patients.

Authors:  Julia Riley; Joy R Ross; Dag Rutter; Athol U Wells; Katherine Goller; Ron du Bois; Ken Welsh
Journal:  Support Care Cancer       Date:  2005-06-11       Impact factor: 3.603

5.  COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor.

Authors:  Jon-Kar Zubieta; Mary M Heitzeg; Yolanda R Smith; Joshua A Bueller; Ke Xu; Yanjun Xu; Robert A Koeppe; Christian S Stohler; David Goldman
Journal:  Science       Date:  2003-02-21       Impact factor: 47.728

6.  Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine.

Authors:  Maria G Scordo; Edoardo Spina; Marja-Liisa Dahl; Giuliana Gatti; Emilio Perucca
Journal:  Basic Clin Pharmacol Toxicol       Date:  2005-11       Impact factor: 4.080

7.  Subgrouping of fibromyalgia patients on the basis of pressure-pain thresholds and psychological factors.

Authors:  Thorsten Giesecke; David A Williams; Richard E Harris; Thomas R Cupps; Xiaoming Tian; Thomas X Tian; Richard H Gracely; Daniel J Clauw
Journal:  Arthritis Rheum       Date:  2003-10

Review 8.  Some aspects of genetic polymorphism in the biotransformation of antidepressants.

Authors:  Kim Brøsen
Journal:  Therapie       Date:  2004 Jan-Feb       Impact factor: 2.070

9.  Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions.

Authors:  Adrián LLerena; Pedro Dorado; Roland Berecz; Antonio P González; Eva M Peñas-LLedó
Journal:  Eur J Clin Pharmacol       Date:  2004-01-16       Impact factor: 2.953

Review 10.  The role of the central nervous system in the generation and maintenance of chronic pain in rheumatoid arthritis, osteoarthritis and fibromyalgia.

Authors:  Yvonne C Lee; Nicholas J Nassikas; Daniel J Clauw
Journal:  Arthritis Res Ther       Date:  2011-04-28       Impact factor: 5.156

View more
  3 in total

1.  Oxycodone/naloxone versus tapentadol in real-world chronic non-cancer pain management: an observational and pharmacogenetic study.

Authors:  Jordi Barrachina; Cesar Margarit; Javier Muriel; Santiago López-Gil; Vicente López-Gil; Amaya Vara-González; Beatriz Planelles; María-Del-Mar Inda; Domingo Morales; Ana M Peiró
Journal:  Sci Rep       Date:  2022-06-16       Impact factor: 4.996

2.  Patient-reported outcomes in a large community-based pain medicine practice: evaluation for use in phenotype modeling.

Authors:  David A Juckett; Fred N Davis; Mark Gostine; Philip Reed; Rebecca Risko
Journal:  BMC Med Inform Decis Mak       Date:  2015-05-28       Impact factor: 2.796

3.  A novel paradigm to evaluate conditioned pain modulation in fibromyalgia.

Authors:  Cynthia J Schoen; Jacob N Ablin; Eric Ichesco; Rupal J Bhavsar; Laura Kochlefl; Richard E Harris; Daniel J Clauw; Richard H Gracely; Steven E Harte
Journal:  J Pain Res       Date:  2016-09-26       Impact factor: 3.133

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.